An Early Phase 1 interventional study of Fluconazole Powder in Candidiasis, sponsored by Sutphin Drugs. Status unknown at 2 sites in 2 countries. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-06.
Sponsored by Sutphin Drugs · Early Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fluconazole in Candidiasis — 1 open to participants now, 1 under way, none of them phase 3. Fluconazole · Candidiasis.
Among the 19 studies testing fluconazole in Candidiasis, this one is the 9th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 1, and was the 19th registered.
132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.
Browse Candidiasis studies →1 of the 19 studies testing fluconazole in Candidiasis is open now, in 3 countries. Recruiting first, the newest first:
Bochud Pierre-Yves · Sites in Belgium, France, Switzerland
Ages 18+
By country, each count listing its studies:
Fluconazole: first FDA approval 1990 (DIFLUCAN). What it is approved for, and how studies give it, is on its page →
Of the 6 Candidiasis studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 6 · Phase 4 4
First in 1996; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 91 across 86 interventional studies indexed under Candidiasis.
Median enrollment 228 across the 16 interventional studies. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 19 have an industry lead sponsor. The 10 most frequent:
Sutphin Drugs is the lead sponsor of 4 studies on the registry; none are open to participants now.
Sutphin Drugs has 1 study filed under Candidiasis — fewer than ten, so there is no comparison to draw.
1 of the studies testing fluconazole in Candidiasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03828773Bochud Pierre-YvesPTX3-targeted Antifungal Prophylaxis | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing fluconazole in Candidiasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and Pfizer (Diflucan®) 40 mg/ml 35 ml Fluconazole Suspension Under Fed Condition
The study is to be conducted as an open-label, randomized, single-dose, 2-way crossover, relative bio availability study performed on 200 healthy adult volunteers. A total 200 subjects will be assessed for AUC for 72 hours after administration of flucanazole suspension
Inclusion Criteria Male and females between the ages of 18 and 35 years
Exclusion Criteria:
History or presence of significant:
In addition, history or presence of:
alcoholism or drug abuse within the past year; or idiosyncratic reaction to fluconazole or other azoles. Subjects who have used any drugs or other substances known to be strong inhibitors of CYP (cytochrome P450) enzymes within 10 days prior to first dose.
Subjects who have used any drugs or other substances known to be strong inducers of CYP (cytochrome P450) enzymes within 30 days prior to first dose.
Subjects who have been anormal diet during the 30 days prior to the first dosing.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
Drug: Fluconazole Powder
The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
Drug: Fluconazole Powder
The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
Bio availability
To measure the AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours after a single dose administration of Under Fed Condition
Time frame: 24 hours
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2020; primary completion for Dec 2020, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluconazole
Sutphin Drugs